Lumos Pharma, Inc. (LUMO) |
|
7.33 0.08 (1.1%)
|
06-26 23:18 |
|
Open: |
7.42 |
Pre. Close: |
7.25 |
|
High:
|
7.6 |
Low:
|
7.25 |
|
Volume:
|
6,049 |
Market Cap:
|
61(M) |
|
|
|
|
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.6 - 7.63 |
7.63 - 7.65 |
|
Low:
|
7.18 - 7.21 |
7.21 - 7.24 |
|
Close:
|
7.28 - 7.32 |
7.32 - 7.37 |
|
Technical analysis |
as of: 2022-06-24 4:41:27 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 8.97 One year: 9.82 |
| Support: |
Support1: 6.51 Support2: 5.41 |
| Resistance: |
Resistance1: 7.68 Resistance2: 8.4 |
| Pivot: |
7.17  |
| Moving Average: |
MA(5): 7.05  MA(20): 7.3
MA(100): 8.63 MA(250): 8.67 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 38.5 %D(3): 29.5 |
| RSI: |
RSI(14): 48.5 |
| 52-week: |
High: 11.52 Low: 6.15 |
| Average Vol(K): |
3-Month: 14 (K) 10-Days: 11 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LUMO ] has closed below upper band by 40.6%. Bollinger Bands are 3.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 26 Jun 2022
Finnair Plus Status Match for Eurobonus, Flying Blue & Miles&More Members - LoyaltyLobby
Thu, 23 Jun 2022
Lorry smashes through stone wall and crashes onto rail tracks in East Lothian disrupting cross-border LNER and LUMO trains - STV News
Mon, 20 Jun 2022
Rail strikes: Which trains are still running during RMT strike action? - Metro.co.uk
Thu, 16 Jun 2022
I tried to eat and drink my way into making a profit from a first class train ticket - The Tab
Wed, 15 Jun 2022
Insiders who bought in the last 12 months lose an additional US$7.7k as Lumos Pharma, Inc. (NASDAQ:LUMO) drops to US$56m - Simply Wall St
Tue, 07 Jun 2022
Managing Director of both Lumo and Hull Trains appointed - Railway Gazette
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
5.04e+006 (%) |
|
% Held by Institutions
|
33.4 (%) |
|
Shares Short
|
21 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.107e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-13 |
|
Return on Assets (ttm)
|
629.1 |
|
Return on Equity (ttm)
|
-17.1 |
|
Qtrly Rev. Growth
|
230000 |
|
Gross Profit (p.s.)
|
489.13 |
|
Sales Per Share
|
-32.19 |
|
EBITDA (p.s.)
|
250000 |
|
Qtrly Earnings Growth
|
-3.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.23 |
|
Price to Cash Flow
|
0.59 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
18230 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-03-18 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
